However, rising instances of clinical failure of drugs on entering clinical trial phase is expected to hamper the growth of specialty CROs market. According to the U.S. FDA data, there were more than 25 clinical trials failure cases in the year 2017, most of which were targeted towards cancer treatment. Furthermore, there is risk of intellectual property theft in which crucial data related with drug candidate under investigation is vulnerable to misuse. This is especially case in CROs which are established in developing countries such as India, China.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients